IV Fluid Supply Updates

Alopecia Areata

Below is a list of our alopecia areata studies that are currently enrolling.

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata

  • Population: Patients aged 6 years to less than 18 years
  • Study Condition: Severe Alopecia Areata
  • Study Design: This is a Phase 3, placebo-controlled, randomized, double-blind research study evaluating the efficacy, safety, and PK of baricitinib in children from 6 years to less than 18 years of age with severe alopecia areata. The study is divided into 4 periods: a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week posttreatment follow-up period. If the subject meets all eligibility criteria they will be randomized to receive either baricitinib high dose, baricitinib low dose, or placebo for 36 weeks. Participants will then be transitioned into the long-term extension treatment period. Subjects will attend 18 clinic visits for up to 145 weeks.
  • Compensation may be provided

A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata

  • Population: Patients 18 years of age to less than 64 years of age
  • Study Condition: Severe Alopecia Areata
  • Study Design: The purpose of this study is to evaluate the efficacy and safety of upadacitinib in adults and adolescents. Participation in this research study will take approximately 169 weeks with 17 visits in that time. This research study includes three phases; a screening phase, treatment phase, and a follow-up phase. The length of the screening period varies from 1 to 35 days, depending on therapies that must be washed out or discontinued before initiation of treatment. Patients who meet all eligibility criteria will be randomized to receive upadacitinib or placebo for the first 24 weeks. The post-treatment follow-up visit will occur approximately 30 days after the last study drug dose.
  • Compensation will be provided

Please contact Dr. Veronica Emmerich for more information regarding ongoing alopecia areata studies.

Email: emmerich@musc.edu

Phone: 843-876-0110